


PHARMACEUTICAL 2020



DiaMedica Therapeutics Inc. Rank 320 of 362





PHARMACEUTICAL 2020



DiaMedica Therapeutics Inc. Rank 320 of 362

The relative strengths and weaknesses of DiaMedica Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DiaMedica Therapeutics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 79% points. The greatest weakness of DiaMedica Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 354% points.

The company's Economic Capital Ratio, given in the ranking table, is -665%, being 362% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	8,836
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,318
Liabilities, Non-Current	118
Other Assets	153
Other Compr. Net Income	2.0
Other Expenses	31
Other Liabilities	0
Other Net Income	975
Property and Equipment	64
Research and Development	7,900
Revenues	0
Selling, General and Administrative Expense	3,693

Output Variable	Value in 1000 USD
Assets	9,053
Liabilities	1,436
Expenses	11,624
Stockholders Equity	7,617
Net Income	-10,649
Comprehensive Net Income	-10,648
Economic Capital Ratio	-665%